ArticleBMC primary care2026
Reclassification of office blood pressure categories according to the 2024 European Society of Cardiology guidelines and its implications for clinical practice in primary care: a cross-sectional study.
Article in BMC primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 2024 European Society of Cardiology (ESC) guidelines retained the diagnostic threshold for hypertension (≥ 140/90 mmHg) but revised the classification of office blood pressure (BP) values below this threshold and introduced a risk-based management strategy. However, there are limited data regarding the impact of these changes on primary care practice.
aimThe aim of this study was to evaluate the reclassification of office BP categories among primary care patients according to the 2024 ESC guidelines for elevated BP and hypertension, and to assess achievement of target BP based on these revised targets.
methodsThis retrospective cross-sectional study included 882 individuals aged 18 years or older registered at a family health center (FHC) in Izmir. Participants were classified according to the 2018 ESC/European Society of Hypertension (ESH) and 2024 ESC criteria. Cardiovascular risk was determined using the Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons (SCORE2-OP) algorithms. The primary endpoint was the change in office BP classification, and the secondary endpoint was the proportion of patients achieving the BP target.
resultsOverall, 29.5% of the participants had hypertension. Under the 2018 ESC/ESH guidelines, 70.5% of individuals had optimal, normal, or high-normal office BP, whereas under the 2024 ESC guidelines, only 17.1% had non-elevated BP. Applying the 2024 criteria, 53.4% of all participants were placed in the elevated BP group, with 75.7% of individuals previously considered below the hypertension threshold reclassified into this group. The proportion of treated patients achieving the prespecified BP target decreased from 53.5% under the 2018 ESC/ESH criteria to 30.8% under the 2024 ESC framework.
conclusionApplying the 2024 ESC office BP criteria reclassified more than half of our participants into the newly defined "elevated BP" group. This update could influence daily clinical practice by changing how clinicians determine which patients require closer assessment, ongoing follow-up, and treatment to achieve target BP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.